Alkermes plc (ALKS) Unusual Options Activity Today

Checking ALKS unusual options activity helps you spot when traders are making outsized bets on Alkermes plc before the broader market catches on. Alkermes plc's unusual options activity flags contracts trading at multiples of their average daily volume, often signaling that informed money is positioning ahead of a catalyst. Use our scanner to monitor ALKS unusual options activity today and surface the prints that deserve a second look.

Unusual options flow typically refers to trades where volume vastly exceeds open interest at a given strike, or where total contract volume on a name spikes well above its norm. Watching ALKS unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking ALKS unusual options volume across calls and puts helps you separate hedging activity from genuinely speculative positioning, and ALKS unusual options flow data becomes especially valuable around earnings, product launches, and macro events.

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases.

The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Catalysts rarely arrive without a footprint, and ALKS unusual options activity is often where that footprint shows up first. Our scanner tracks Alkermes plc's unusual options flow in real time, ranks prints by volume-to-open-interest, premium spent, and aggressor side, and separates real conviction from noise. Whether you're looking at ALKS unusual options volume on the call side or chasing put sweeps, Alkermes plc's unusual options flow today is one click away, so put it on your radar before the headlines hit.